Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lanthanum carbonate→

Lanthanum carbonate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
587-26-8
PubChem CID
168924
Molecular formula
C3La2O9
Molecular weight
457.84 g/mol
Drug class
Lanthanum(III) phosphate-binding agentnon-calcium phosphate binder
Mechanism of action
Dissociates in the gastrointestinal tract and binds dietary phosphate, forming insoluble lanthanum-phosphate complexes that are eliminated in faeces, reducing intestinal phosphate absorption.
Indications / reported uses
  • Control of serum phosphate in patients with chronic kidney disease on dialysis; chewable or oral-powder formulation must be taken with meals according to the product label

Sources: US DailyMed — FOSRENOL (lanthanum carbonate) · NLM MeSH — Lanthanum carbonate · FDA product information

Identification source: PubChem record (CID 168924). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lanthanum carbonate Environmental Risk Assessment (ERA) (the Lanthanum carbonate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.